Filing Flows › Capricor Therapeutics (CAPR) › Recalls, complaints & regulation
Capricor Therapeutics (CAPR): clinical trials
Capricor Therapeutics (CAPR) beyond its filings: 2 active clinical trials.
Capricor Therapeutics' latest quarter
Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%, net loss $7.1M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Capricor Therapeutics have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.